CAJ | 학술논문

目的评价奈达铂(NDP)联合替加氟(Fr-207)治疗晚期食管癌的疗效和毒副反应.方法 65例晚期食管癌患者中,初次化疗患者27例,术后接受辅助化疗38例.NDP 20 ms/m2,静脉滴注2 h,第1～5天;Fr-207 500 m/m2,静脉滴注8 h,第1～5天;21 d为1个周期.结果 65例患者共完成193个化疗周期,其中可评价疗效的患者63例.27例初次化疗的患者中,CR 6例,PR 16例,有效率为81.5%;36例复治的患者中,CR6例,PR 10例,有效率为44.4%.所有患者的中位疾病进展时间(TTP)为5.6个月,中位生存时间为9.3个月,1年生存率为24.9%.临床毒副反应为恶心、呕吐,患者均能耐受.63例可评价毒副反应的患者中,有2例(3.2%)出现Ⅲ～Ⅳ度中性粒细胞降低.结论 NDP联合FT-207对晚期食管癌疗效肯定,毒副反应轻,可作为治疗晚期食管癌的主要治疗方案.
목적 평개내체박(NDP)연합체가불(Fr-207)치료만기식관암적료효화독부반응.방법 65례만기식관암환자중,초차화료환자27례,술후접수보조화료38례.NDP 20 ms/m2,정맥적주2 h,제1～5천;Fr-207 500 m/m2,정맥적주8 h,제1～5천;21 d위1개주기.결과 65례환자공완성193개화료주기,기중가평개료효적환자63례.27례초차화료적환자중,CR 6례,PR 16례,유효솔위81.5%;36례복치적환자중,CR6례,PR 10례,유효솔위44.4%.소유환자적중위질병진전시간(TTP)위5.6개월,중위생존시간위9.3개월,1년생존솔위24.9%.림상독부반응위악심、구토,환자균능내수.63례가평개독부반응적환자중,유2례(3.2%)출현Ⅲ～Ⅳ도중성립세포강저.결론 NDP연합FT-207대만기식관암료효긍정,독부반응경,가작위치료만기식관암적주요치료방안.
Objective To investigate the efficacy and toxicity of nedaplatin combined with tegnfur in the treatment for patients with advanced esophageal cancer. Methods Among the 65 patients with advanced esophageal cancer, 27 had no history of prior chemotherapy and the other 38 had ever received postoperative adjuvant chemotherapy before. The median age of those eases was 58.0 years. Nedaplatin was given daily by intravenous infusion at a dose of 20 mg/m2 for 2 hours and tegafur at a dose of 500 mg/m2 for 8 hours on D1 ～ D5, every 21 days as a cycle. Results 193 cycles of chemotherapy were accomplished in the 65 patients, and 63 patients were evaluable for response evaluation. Of 27 patients with no prior history of chemotherapy, 6 achieved complete response and 16 partial response, with a response rate ( CR + PR) of 81.5%. Among the 36 patients who had ever received postoperative adjuvant chemotherapy, 6 obtained complete response and 10 partial response with a response rate ( CR + PR) of 44.4%. The overall median time to tumor progression in this series was 5.6 months. The overall median actuarial survival was 9.3 months, and the one-year survival rate was 24.9%. Nausea and vomiting were the major toxieities, but were mild and well tolerable. Grade 3 to 4 neutropenia was only observed in two patients (3.2%). Conclusion The regimen of nedaplatin combined with tegafur is effective and tolerable for the treatment of advanced esophageal cancer.